Barclays
ZBIO

Barclays’s Zenas BioPharma ZBIO Stock Holding History

Barclays’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
115,965
+86,355
+292% +$1.72M ﹤0.01% 2133
2026
Q1 		$579K Sell
29,610
-4,767
-14% -$107K ﹤0.01% 3100
2025
Q4 		$1.25M Buy
34,377
+11,501
+50% +$378K ﹤0.01% 3286
2025
Q3 		$508K Sell
22,876
-4,937
-18% -$80.4K ﹤0.01% 3802
2025
Q2 		$270K Buy
27,813
+11,653
+72% +$113K ﹤0.01% 4101
2025
Q1 		$128K Sell
16,160
-7,779
-32% -$60.9K ﹤0.01% 4304
2024
Q4 		$196K Buy
23,939
+8,439
+54% +$132K ﹤0.01% 4324
2024
Q3 		$262K Buy
+15,500
New +$279K ﹤0.01% 4155

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Barclays's ZBIO Position: Q2 2026 in Review

Barclays increased its Zenas BioPharma (ZBIO) stake by 292% in Q2 2026, buying an estimated $1.72M and bringing the position to 115,965 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Barclays first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Barclays held 115,965 shares of Zenas BioPharma worth $2.94M as of Q2 2026.
  • Barclays bought 86,355 Zenas BioPharma shares in Q2 2026, an estimated $1.72M.
  • Zenas BioPharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2133 holding.
  • Barclays first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.